Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Gene Therapy
Studies from Harvard University, Howard Hughes Medical Institute yield new information about cancer gene therapy
February 27th, 2007
Investigators publish new data in the report "The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma." According to recent research published in the journal Clinical Cancer Research, "Germ line VHL tumor suppressor gene loss-of-function mutations cause von Hippel-Lindau disease, which is associated with an increased risk of central nervous system hemangioblastomas, clear cell renal carcinomas, and pheochromocytomas. Somatic VHL mutations are also common in sporadic clear cell renal carcinomas." "The VHL gene product, pVHL, is part of a ubiquitin ligase complex that targets the alpha-subunits of the heterodimeric transcription factor...
Source: Cancer Weekly (2007-02-27)
|
